270
Participants
Start Date
June 5, 2025
Primary Completion Date
February 27, 2029
Study Completion Date
February 27, 2029
Antibody-drug conjugate (ADC)
ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.
RECRUITING
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg, Leuven
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
University of Miami - Sylvester Comprehensive Cancer Center, Miami
NOT_YET_RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
University Of Texas MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
University of Colorado Denver, Aurora
NOT_YET_RECRUITING
Universitätsklinikum Essen West German Tumor Center, Essen
NOT_YET_RECRUITING
Royal Marsden, London
Lead Sponsor
Adcendo ApS
INDUSTRY